.webp)
Immunethep is developing broad-coverage anti-bacterial immunotherapies targeting a novel virulence mechanism used by different pathogenic bacteria that allows them to cause the infection.
Their most advanced product is the Paragon Novel Vaccine (PNV), the first Vaccine in the world that simultaneously prevents infections from 5 of the most critical bacteria for mankind (S.aureus, S.pneumoniae, K.pneumoniae, E.coli, and S.agalactiae) which greatly reduces the need for antibiotics contributing to reducing Antimicrobial Resistance (AMR).
The funding raised through this campaign will enable Immunethep to speed up the procedures to start the clinical trials of PNV, thus shortening the time for this vaccine to be available in the market.
Antimicrobial Resistance (AMR) is leading to an uncontrolled rise of superbugs. This global threat kills around 1.27 million people annually and is estimated to increase 8-fold by 2050, reaching 10 million yearly deaths. Today AMR costs around $30 billion a year to the EU and USA health systems.
According to the CDC (Center for Disease and Control Prevention), the five bacteria addressed by PNV are responsible for 80% of all life-threatening human infections. The therapies used to fight superbugs are antibiotics (treatment) and vaccines (prevention). The antibiotics are increasingly less effective (four of the bacteria mentioned are highly resistant to antibiotics) and contribute to AMR growth.
Immunethep has successfully concluded the preclinical trials with PNV. The promotor is now looking for funding to test further. A significant part of that funding is already assured with the support of a 2.5 million euro grant awarded to Immunethep by the European Innovation Council.
PNV will become the first ever multiple bacteria vaccine in the world to enter human clinical trials. This has been recently acknowledged by the World Health Organization in its report on Bacterial vaccines in clinical and preclinical development.
Direct
The use of the vaccine in the prevention of these bacterial diseases greatly reduces the need for antibiotics in the treatment, which contributes to reducing Antimicrobial Resistance (AMR).
Indirect
Direct
The use of the vaccine in the prevention of these bacterial diseases greatly reduces the need for antibiotics in the treatment, which contributes to reducing Antimicrobial Resistance (AMR).
Indirect
Promoter website
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
0%
25000000
minimum
25000000
target
25000000
maximum
Closed
open projects you may likeGoparity allowed me to dive into the investment world in a responsible and conscious way. With an incredible support team, I invested in project with meaning and impact!
Investor since 2019
It’s great to be part of Goparity’s family! Costumer Support treats me like I’m one of them, plus its business model allows me to support sustainable and eco-friendly projects. What more cloud I ask for? :)
Investor since 2023
Economic development and ecological preservation shouldn’t have their back turned on each other, we should face the future with the opposite perspective if we want a future at all! Goparity allows that.
Investor since 2019
A good option for those who like to invest in crowdfunding. Moreover knowingly it supports a more eco-friendly Portugal.
Investor since 2020
Goparity has great Customer Support and makes me want to be friends with all the people behind the scenes who are so focused on creating a positive impact in the world.
Investor since 2017
Joining Goparity was very simple and fast. One can see that there is a good team behind the scenes!
Investor since 2020
grow it every monthTurn occasional investments into a disciplined, diversified strategy. Set your preferences, and Auto-Investment will match opportunities automatically — so your money work while life gets busy.
Get an instant simulation and receive an offer within 48 hours.
Track projects, manage investments, and follow your returns.
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)